[Immunological efficiency of DNA vaccine targeting dendritic cells against tumor].
To construct the DNA vaccine containing ovalbumin (OVA) and Fc fusion gene targeting dentritic cells (DCs) and evaluate its anti-tumor efficiency in an E.G7-OVA-bearing tumor model. Constructed OVA-Fc-pcDNA3.1 plasmids were transfected into CHO cells with lipofectamine and the in vitro expression of OVA-Fc was determined by flow cytometry and ELISA. (51)Cr-relaese assay was used to determine the anti-tumor activity of cytotoxic T lymphocytes (CTLs) from splenocytes of immunized mice. According to tumor volume and survival time of the mice, the therapeutic effect of this vaccine was evaluated in E.G7-OVA-bearing tumor model. DNA sequencing and restriction endonuclease digestion analysis indicated that the recombinant expression vector OVA-Fc-pcDNA3.1 had been constructed successfully. OVA-Fc expression could be detected in CHO cells transfected with OVA-Fc-pcDNA3.1 by ELISA and flow cytometry. The DNA vaccine containing OVA-Fc fusion gene inhibited tumor's growth and prolonged the time of tumor-bearing mice due to elicit the CTL-mediated anti-tumor immunity. OVA-Fc-pcDNA3.1 DNA vaccine targeting dendritic cells can elicit the CTL-mediated anti-tumor immunity, which lays the foundation for further clinical experiments.